0
April 1982, Vol 136, No. 4 >
Article | April 1982

A Benefit-Cost Analysis of Mumps Vaccine FREE

Jeffrey P. Koplan, MD, MPH; Stephen R. Preblud, MD
[+] Author Affiliations

Reprint requests to Office of Program Planning and Evaluation, Centers for Disease Control, Atlanta, GA 30333 (Dr Koplan).


Am J Dis Child. 1982;136(4):362-364. doi:10.1001/archpedi.1982.03970400080021.
Text Size: A A A
Published online
Article
References
Comments

• Applying benefit-cost analysis, we determined the savings in morbidity, mortality, and costs of mumps vaccination in the United States. Using reported mumps incidence rates in a model cohort of 1 million persons followed up for 30 years, mumps vaccination would prevent more than 74,000 cases of mumps and three deaths. Approximating the actual incidence rate of mumps, by assuming that 90% of people are infected by age 30 and 60% of these have had clinical illness, mumps vaccination would prevent more than 540,000 cases of mumps and 23 deaths. A mumps vaccination program, in which mumps was given as part of a measles-mumps-rubella combination, would reduce costs associated with mumps by more than 86%, with a benefit-cost ratio of 7.4:1, using reported incidence rates. The program has a benefit-cost ratio of 39:1 when approximations of actual mumps incidence are used in the analysis. Mumps vaccination is highly cost beneficial.

(Am J Dis Child 1982;136:362-364)

REFERENCES

1 +
Biologics Surveillance Report No. 79: Annual Summary, July-December 1979. Atlanta, Centers for Disease Control, 1980.
2 +
Center for Disease Control: Mumps Surveillance Report: July 1974-December 1976, publication (CDC) 78-8246. US Dept of Health, Education, and Welfare, 1978, pp 1-19.
3 +
Hayden GF, Preblud SR, Orenstein WA, et al:  Current status of mumps and mumps vaccine in the United States . Pediatrics 1978;;62:965-969.
4 +
Center for Disease Control:  Mumps—United States , 1978-1979. Morbidity Mortality Weekly Rep 1979;;28:422-424.
5 +
Centers for Disease Control:  Annual summary , 1979. Morbidity Mortality Weekly Rep 1980;;28:1-120.
6 +
 Bureau of State Services, Immunization Division : School enterer survey, 1978-1979 . Atlanta, Centers for Disease Control, 1980;.
7 +
Dudgeon JA:  Mumps and varicella vaccines . Arch Dis Childh 1980;;55:3-6.
8 +
Koplan JP, Schoenbaum SC, Weinstein MC, et al:  Pertussis vaccine: An analysis of benefits, risks and costs . N Engl J Med 1979;;301:906-911.
9 +
Buynak EB, Hilleman MR, Leagus MB, et al:  Jeryl Lynn strain live attenuated mumps virus vaccine: Influence of age, virus dose, lot, and γ-globulin administration on response . JAMA 1968;;203:9-13.
10 +
Witte JJ, Karchmer AW:  Surveillance of mumps in the United States as a background for use of vaccine . Public Health Rep 1968;;83:95-100.
11 +
Hilleman MR, Buynak EB, Weibal RE, et al:  Live atttenuated mumps-virus vaccine . N Engl J Med 1968;;278:227-232.
12 +
Schwarz AJF, Jackson JE, Ehrenkranz NJ, et al:  Clinical evaluation of a new measles-mumps-rubella trivalent vaccine . Am J Child 1975;;129:1408-1412.
13 +
Phillips CF:  Mumps , in Vaughn VC, McCay AJ, Behrman RE (eds): Textbook of Pediatrics , ed 11. Philadelphia, WB Saunders Co, 1979;.
14 +
Philip RN, Reinhard KB, Lockman DB:  Observation on a mumps epidemic in a "virgin" population . Am J Hyg 1959;;69:91-111.
15 +
Werner CA:  Mumps orchitis and testicular atrophy: I. Occurrence . Ann Intern Med 1950;; 32:1066-1074.
16 +
The Profile of Medical Practice . Chicago, American Medical Association, 1979;, pp 198-203.
17 +
Falk WA:  Survey of mumps admissions, Calgary General Hospital, 1971-1977 . Epidemiol Notes Rep 1980;;4:1-5.
18 +
Hospital indicators. Hospitals 1979;;53:67-72.
19 +
Leon CB, Rones PL: Employment and Unemployment During 1979: An Analysis, Special Labor Force report 234. US Dept of Labor, 1980.
20 +
Statistical Abstract of the United States: 1979 , ed 100. US Bureau of the Census, 1979;.
21 +
Cooper BS, Rice DP: The Economic Cost of Illness Revisited , publication (SSA) 76-11703. US Dept of Health, Education, and Welfare, 1976;, pp 21-36.
22 +
Axnick NW, Shavell SM, Witte JJ:  Benefits due to immunization against measles . Public Health Rep 1969;;84:673-680.
23 +
Sencer DJ, Axnick NW:  Utilization of cost/benefit analysis in planning prevention programs . Acta Med Scand 1975;;576 ( (suppl) ):123-128.
24 +
Schoenbaum SC, Hyde JN, Bartoshesky L, et al:  Benefit-cost analysis of rubella vaccine policy . N Engl J Med 1976;;294:306-310.
25 +
Wiedermann G, Ambrosch F:  Costs and benefits of measles and mumps immunization in Austria . Bull WHO 1979;;57:625-629.
26 +
Feldman HA:  Mumps , in Evans AS (ed): Viral Infections of Humans: Epidemiology and Control . New York, Plenum Publishing Corp, 1976;, pp 317-336.
27 +
Mortimer PP:  Mumps prophylaxis in the light of a new test for antibody . Br Med J 1978;; 2:1523-1524.
28 +
Just M:  Rentiert die Masem-und/oder Mumps: Impfung für Schweizerische Verhaltnisse? Schweiz Med Wochenschr 1978;;108:1763-1768.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

1 +
Biologics Surveillance Report No. 79: Annual Summary, July-December 1979. Atlanta, Centers for Disease Control, 1980.
2 +
Center for Disease Control: Mumps Surveillance Report: July 1974-December 1976, publication (CDC) 78-8246. US Dept of Health, Education, and Welfare, 1978, pp 1-19.
3 +
Hayden GF, Preblud SR, Orenstein WA, et al:  Current status of mumps and mumps vaccine in the United States . Pediatrics 1978;;62:965-969.
4 +
Center for Disease Control:  Mumps—United States , 1978-1979. Morbidity Mortality Weekly Rep 1979;;28:422-424.
5 +
Centers for Disease Control:  Annual summary , 1979. Morbidity Mortality Weekly Rep 1980;;28:1-120.
6 +
 Bureau of State Services, Immunization Division : School enterer survey, 1978-1979 . Atlanta, Centers for Disease Control, 1980;.
7 +
Dudgeon JA:  Mumps and varicella vaccines . Arch Dis Childh 1980;;55:3-6.
8 +
Koplan JP, Schoenbaum SC, Weinstein MC, et al:  Pertussis vaccine: An analysis of benefits, risks and costs . N Engl J Med 1979;;301:906-911.
9 +
Buynak EB, Hilleman MR, Leagus MB, et al:  Jeryl Lynn strain live attenuated mumps virus vaccine: Influence of age, virus dose, lot, and γ-globulin administration on response . JAMA 1968;;203:9-13.
10 +
Witte JJ, Karchmer AW:  Surveillance of mumps in the United States as a background for use of vaccine . Public Health Rep 1968;;83:95-100.
11 +
Hilleman MR, Buynak EB, Weibal RE, et al:  Live atttenuated mumps-virus vaccine . N Engl J Med 1968;;278:227-232.
12 +
Schwarz AJF, Jackson JE, Ehrenkranz NJ, et al:  Clinical evaluation of a new measles-mumps-rubella trivalent vaccine . Am J Child 1975;;129:1408-1412.
13 +
Phillips CF:  Mumps , in Vaughn VC, McCay AJ, Behrman RE (eds): Textbook of Pediatrics , ed 11. Philadelphia, WB Saunders Co, 1979;.
14 +
Philip RN, Reinhard KB, Lockman DB:  Observation on a mumps epidemic in a "virgin" population . Am J Hyg 1959;;69:91-111.
15 +
Werner CA:  Mumps orchitis and testicular atrophy: I. Occurrence . Ann Intern Med 1950;; 32:1066-1074.
16 +
The Profile of Medical Practice . Chicago, American Medical Association, 1979;, pp 198-203.
17 +
Falk WA:  Survey of mumps admissions, Calgary General Hospital, 1971-1977 . Epidemiol Notes Rep 1980;;4:1-5.
18 +
Hospital indicators. Hospitals 1979;;53:67-72.
19 +
Leon CB, Rones PL: Employment and Unemployment During 1979: An Analysis, Special Labor Force report 234. US Dept of Labor, 1980.
20 +
Statistical Abstract of the United States: 1979 , ed 100. US Bureau of the Census, 1979;.
21 +
Cooper BS, Rice DP: The Economic Cost of Illness Revisited , publication (SSA) 76-11703. US Dept of Health, Education, and Welfare, 1976;, pp 21-36.
22 +
Axnick NW, Shavell SM, Witte JJ:  Benefits due to immunization against measles . Public Health Rep 1969;;84:673-680.
23 +
Sencer DJ, Axnick NW:  Utilization of cost/benefit analysis in planning prevention programs . Acta Med Scand 1975;;576 ( (suppl) ):123-128.
24 +
Schoenbaum SC, Hyde JN, Bartoshesky L, et al:  Benefit-cost analysis of rubella vaccine policy . N Engl J Med 1976;;294:306-310.
25 +
Wiedermann G, Ambrosch F:  Costs and benefits of measles and mumps immunization in Austria . Bull WHO 1979;;57:625-629.
26 +
Feldman HA:  Mumps , in Evans AS (ed): Viral Infections of Humans: Epidemiology and Control . New York, Plenum Publishing Corp, 1976;, pp 317-336.
27 +
Mortimer PP:  Mumps prophylaxis in the light of a new test for antibody . Br Med J 1978;; 2:1523-1524.
28 +
Just M:  Rentiert die Masem-und/oder Mumps: Impfung für Schweizerische Verhaltnisse? Schweiz Med Wochenschr 1978;;108:1763-1768.

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems